Apr 11 |
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
|
Mar 28 |
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
|
Mar 25 |
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
|
Mar 7 |
Lipocine GAAP EPS of -$3.14
|
Mar 7 |
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
|
Mar 6 |
Lipocine to Present at 36th Annual Roth Conference
|
Feb 6 |
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
|
Feb 2 |
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
|
Jan 18 |
Lipocine licenses Tlando testosterone therapy to Verity Pharma
|
Jan 18 |
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
|